Rage Biotech

ADVANCING PRECISION THERAPEUTICS
– RAGE BIOTECH’S COMMITMENT TO
TACKLING CHRONIC INFLAMMATION

Chronic inflammatory diseases can be difficult to treat. The Receptor for Advanced Glycation End-products (RAGE) is an important therapeutic target in a wide range of inflammatory diseases. RAGE Biotech has found a way to block its damaging role in disease by harnessing cutting edge ribonucleic acid (RNA) targeting and therapeutic peptide technologies to bring an effective RAGE modulator to the clinic.

These therapies can block pro-inflammatory signalling through RAGE, and in the case of the company’s RNA medicines, enhance the receptor’s naturally occurring anti-inflammatory splice form. The company’s leading medication, RBr042, is designed to combat chronic lung inflammation and comes in the form of an inhaled RNA oligonucleotide. It is currently in the final stages of preclinical development as a nebulized treatment, in preparation for Phase 1 clinical trials. Additional products in the discovery phase will target afflictions such as liver disease, kidney disease and neurodegenerative disease. With the potential to benefit more than 300 million people worldwide* their breakthrough drugs could minimise the harm and long-term impacts people with chronic inflammatory conditions may suffer.

Website: ragebiotech.com

^{*Global Burden of Disease Study 20, Lancet 386:743-800 (2015)}

_{Year established: 2020
Technology: Biotech and Pharma
Innovation pathway: Monash University spinout
Monash University Faculty: Central Clinical School, Faculty of Medicine, Nursing and Health Science
Investors: IP Group, Monash Investment Holdings, University of Western Australia, Perron Institute, HostPlus
Grants: CUREator fund, mRNA Victoria and NHMRC
Global recognition: Featured Showcase Company at the American Thoracic Society ATS2023 Meeting ‘Respiratory Innovation Summit’ in Washington DC in 2023
Current employees: 1 (End Dec ‘23)}